Personas / Equipo Humano

Cristina Larrosa Espinosa

Buscador de publicaciones

Publicaciones

  • Bruno A, Alvarez-Diduk R, Lara P, Maroli G, Cristina Larrosa Espinosa, López-Miralles S, Mora J, Rodriguez-Hernandez CJ and Merkoçi A.

    Quantum-Capacitance Biosensing Enables Real-Time Monitoring of Naxitamab for Therapeutic Response Stratification in Neuroblastoma.

    Small Science . 6(8): .

    [doi:10.1002/smsc.70349]

  • Cristina Larrosa Espinosa, Simao-Rafael M, Salvador-Marcos N, Muñoz JP, Lavarino C, Chantada G and Mora J.

    Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy

    Frontiers in Pediatrics . 12: 1509645-1509645. Nº de citas: 4

    [doi:10.3389/fped.2024.1509645]

  • Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J.

    Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

    PEDIATRIC BLOOD & CANCER . 71(10): . Nº de citas: 1

    [doi:10.1002/pbc.31221]

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): . Nº de citas: 4

    [doi:10.3390/cancers16091735]

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Nº de citas: 25

    [doi:10.3390/cancers15194837]

  • Cristina Larrosa Espinosa, Mora J and Cheung NK.

    Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2

    Cancers . 15(14): . Nº de citas: 20

    [doi:10.3390/cancers15143729]

  • Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.

    Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report

    Cancers . 15(9): . Nº de citas: 23

    [doi:10.3390/cancers15092535]

  • Ferrari A, Provenzano S, Prampolini C, van der Graaf W, Husson O, Morgan JD, Quarello P, Cristina Larrosa Espinosa, Castañeda-Heredia A, Peccatori F, Stark D, Laurence V, Gaspar N, Poirel HA, Van Aelst F, Franceschi E, Saloustros E, Dirksen U, Kienesberger A, Schneider C, Murphy I, Kosir U, Rizvi K, Fiorente M, Casali P and Trama A.

    Advancing cancer care for adolescents and young adults: the role of the European Network of Expertise.

    ESMO Open . 11(10): 108542-108542.

    [doi:10.1016/j.esmoop.2026.108542]